RxDoctor Payments Data

David Harrison, MD

Internal Medicine · Crestview, FLNPI 1497702302

Payments from drug & device makers

$458in general payments, 2019–2025

Across 23 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$58
  • Lilly USA, LLC$57
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$51
  • Novartis$43
  • Biosense Webster, Inc.$32
  • AbbVie$30
  • plus $188 from 10 others

What the payments were for

  • Food & beverage$458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$458 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$125,224
Medicare patients
288
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban374$115,828
XifaxanRifaximin33$52,173
NuplazidPimavanserin Tartrate21$50,779
MyrbetriqMirabegron215$48,313
AustedoDeutetrabenazine18$42,335
OzempicSemaglutide39$39,206
XareltoRivaroxaban135$37,814
LinzessLinaclotide127$33,579
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$22,258
JanuviaSitagliptin Phosphate78$21,867
SecuadoAsenapine25$16,869
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog58$15,869
Breo ElliptaFluticasone/Vilanterol33$14,104
BrilintaTicagrelor59$10,967
MovantikNaloxegol Oxalate48$9,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$51$52,17333 claims
AbbVieLinzess, Restasis$30$37,199138 claims
AstraZenecaBrilinta, Farxiga, Lokelma$19$19,31789 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Crestview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →